Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
MRK

MRK - Merck & Co Inc Stock Price, Fair Value and News

129.50USD+0.13 (+0.10%)Market Closed

Market Summary

MRK
USD129.50+0.13
Market Closed
0.10%

MRK Alerts

  • Big jump in Earnings (Y/Y)

MRK Stock Price

View Fullscreen

MRK RSI Chart

MRK Valuation

Market Cap

327.6B

Price/Earnings (Trailing)

142.08

Price/Sales (Trailing)

5.34

EV/EBITDA

61.43

Price/Free Cashflow

30.08

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

6.37%

Return on Equity

5.71%

Return on Assets

2.18%

Free Cashflow Yield

3.32%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

61.4B

Rev. Growth (Yr)

8.89%

Rev. Growth (Qtr)

7.82%

MRK Earnings

Earnings (TTM)

2.3B

Earnings Growth (Yr)

68.81%

Earnings Growth (Qtr)

488.42%

Breaking Down MRK Revenue

52 Week Range

106.26129.81
(Low)(High)

Last 7 days

-0.9%

Last 30 days

0.5%

Last 90 days

6.5%

Trailing 12 Months

19.1%

How does MRK drawdown profile look like?

MRK Financial Health

Current Ratio

1.25

Debt/Equity

0.77

Debt/Cashflow

0.47

MRK Investor Care

Dividend Yield

2.29%

Dividend/Share (TTM)

2.96

Buy Backs (1Y)

0.18%

Diluted EPS (TTM)

0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202461.4B000
202357.9B58.3B59.3B60.1B
202254.0B57.2B59.0B59.3B
202141.0B43.0B45.2B48.7B
202040.4B38.0B36.5B42.4B
201943.1B44.4B46.0B39.1B
201840.7B41.3B41.7B42.3B
201739.9B40.0B39.8B40.1B
201639.4B39.4B39.9B39.8B
201541.4B40.2B39.8B39.5B
201443.6B43.5B43.1B42.2B
201346.2B44.9B44.5B44.0B
201248.2B48.4B47.8B47.3B
201146.1B47.0B47.8B48.0B
201033.5B38.9B44.0B46.0B
200924.6B25.6B27.0B27.4B
2008024.1B24.0B23.9B
200700024.2B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Merck & Co Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 04, 2024
deluca richard r.
sold (taxes)
-1,703,530
127
-13,360
evp&pres, merck animal heallth
May 04, 2024
klobuchar michael a
acquired
113,101
127
887
evp - chief strategy officer
May 04, 2024
oosthuizen johannes jacobus
acquired
116,289
127
912
president, u.s. market
May 04, 2024
smart dalton
sold (taxes)
-38,508
127
-302
svp fin. - global controller
May 04, 2024
smart dalton
acquired
78,036
127
612
svp fin. - global controller
May 04, 2024
oosthuizen johannes jacobus
sold (taxes)
-57,379
127
-450
president, u.s. market
May 04, 2024
klobuchar michael a
sold (taxes)
-55,721
127
-437
evp - chief strategy officer
May 04, 2024
deluca richard r.
acquired
3,458,840
127
27,126
evp&pres, merck animal heallth
May 03, 2024
smart dalton
acquired
262,420
128
2,046
svp fin. - global controller
May 03, 2024
smart dalton
sold (taxes)
-108,380
128
-845
svp fin. - global controller

1–10 of 50

Which funds bought or sold MRK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
7.53
813,183
3,775,580
0.30%
Jun 11, 2024
CYPRESS ASSET MANAGEMENT INC/TX
reduced
-0.78
971,758
5,472,760
1.48%
Jun 11, 2024
Jackson Wealth Management, LLC
added
3.53
1,266,000
6,267,000
0.78%
Jun 11, 2024
American Trust
reduced
-39.98
-134,279
356,529
0.03%
Jun 10, 2024
Hamilton Wealth, LLC
added
4.48
665,890
3,183,160
0.99%
Jun 07, 2024
Railway Pension Investments Ltd
reduced
-0.4
33,719,900
197,821,000
1.93%
Jun 06, 2024
WESTWOOD HOLDINGS GROUP INC
reduced
-0.6
444,000
2,628,000
0.02%
Jun 05, 2024
Objective Capital Management, LLC
added
0.43
110,569
623,242
0.42%
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
0.42
133,287,000
716,221,000
1.33%
Jun 04, 2024
Tactive Advisors, LLC
added
31.69
158,914
426,531
0.23%

1–10 of 50

Are Funds Buying or Selling MRK?

Are funds buying MRK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRK
No. of Funds

Unveiling Merck & Co Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.66%
244,767,034
SC 13G/A
Jan 26, 2024
blackrock inc.
8.0%
201,836,434
SC 13G/A
Feb 09, 2023
vanguard group inc
8.96%
227,205,978
SC 13G/A
Feb 03, 2023
blackrock inc.
8.5%
215,011,385
SC 13G/A
Feb 09, 2022
vanguard group inc
8.36%
211,202,531
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
198,224,264
SC 13G/A
Feb 10, 2021
vanguard group inc
8.24%
208,410,644
SC 13G/A
Feb 05, 2021
blackrock inc.
7.8%
196,213,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.26%
210,542,333
SC 13G/A
Feb 05, 2020
blackrock inc.
7.5%
190,783,225
SC 13G/A

Recent SEC filings of Merck & Co Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading

Peers (Alternatives to Merck & Co Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.94% -10.00%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.54% 19.05%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-4.21% 34.20%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.61% -29.78%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-6.10% -18.51%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
1.81% 133.24%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.31% -21.88%
9.66
2.43
54.01% 364.56%
3.7B
4.6B
-9.61% -18.87%
-484.91
0.82
-0.06% 94.55%
2.3B
9.0B
-13.20% -15.57%
-4.97
0.25
10.01% -27.45%
2.0B
676.2M
-1.62% -15.25%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-16.75% 6.10%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-2.94% -47.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-19.67% -19.01%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.66%
-0.32
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Merck & Co Inc News

Latest updates
Defense World6 hours ago

Merck & Co Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue7.8%15,77514,63115,96215,03514,48713,83014,95914,59315,90113,52113,15411,40210,62710,06410,9299,35312,0574,14912,39711,76010,816
  S&GA Expenses-11.4%2,4832,8042,5192,7022,4792,6872,5202,5122,3232,8302,3362,2812,1872,4372,0602,0852,5551,7292,5892,7122,425
  R&D Expenses-58.5%3,9929,6273,30713,3214,2763,7754,3992,7982,5763,0682,4454,3212,4125,7713,3492,0852,2092,4003,2042,1891,931
EBITDA Margin53.5%0.09*0.06*0.15*0.12*0.29*0.31*0.32*0.35*0.32*0.32*0.19*0.14*---------
Income Taxes210.1%903-82087063782549633053855485.006955032387.00380396619306440615205
Earnings Before Taxes377.1%5,670-2,0465,620-5,3353,6503,5133,5834,4874,8613,9095,2661,7172,987-2,9832,7062,7413,838-1,5022,3473,2593,067
EBT Margin102.6%0.06*0.03*0.13*0.09*0.26*0.28*0.29*0.32*0.29*0.28*0.15*0.10*---------
Net Income488.4%4,762-1,2264,745-5,9752,8213,0173,2483,9444,3103,7584,5671,5453,179-2,0942,9413,0023,2192,3571,9012,6702,915
Net Income Margin518.5%0.04*0.01*0.08*0.05*0.23*0.24*0.26*0.29*0.26*0.27*0.16*0.13*---------
Free Cashflow400.0%2,229-7436,7102,697332----------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.8%105,849106,675106,727104,469107,796109,160107,081107,095106,668105,69493,49490,68890,84791,58889,80090,61584,91384,39783,33183,96582,354
  Current Assets-2.2%31,44532,16831,95429,97733,40235,72233,56132,11631,18430,26631,05828,66526,90927,76426,57729,34326,17427,48326,14224,29825,351
    Cash Equivalents-18.4%5,5796,8418,6055,6609,78612,77311,2799,7538,6148,16710,0468,6306,8828,1537,40111,1477,4609,9347,8716,6608,077
  Inventory2.4%6,5106,3586,1315,9305,8635,9115,6145,5355,7745,9535,6035,4996,4025,5546,1286,0565,8465,9785,8555,8475,712
  Net PPE0.0%23,04523,05122,52622,23121,75821,42220,42420,05919,74719,27918,56518,06418,29517,00016,91915,78915,26914,29714,28713,86213,506
  Goodwill-0.1%21,18121,19721,18321,19521,20921,20421,16021,21321,25821,26418,86218,87320,21218,88220,24823919,76718,06919,48019,4901,376
  Current Liabilities-2.3%25,09925,69423,09423,39423,13124,23922,99823,16822,31623,87223,72821,90626,36127,32720,40522,17823,48322,22020,68420,08518,543
  Long Term Debt-7.5%31,14233,68333,97234,07228,07428,74528,48228,68430,58630,69022,90724,03324,00225,36026,32126,15621,63722,73622,67722,77122,721
    LT Debt, Non Current-7.5%31,14233,68333,97234,07228,07428,74528,48228,68430,58630,69022,90724,03324,00225,36026,32126,15621,63722,73622,67722,77122,721
Shareholder's Equity7.4%40,36437,58141,24638,74246,90546,05844,52443,31840,95338,25735,86333,38827,03925,40429,27027,74426,30026,00126,92527,73727,670
  Retained Earnings5.2%56,69753,89557,08254,19862,03961,08159,92858,43756,25253,69651,69148,77748,88847,36251,10749,72448,27246,60245,80445,29544,065
  Additional Paid-In Capital0.2%44,59844,50944,35844,21944,46744,37944,24344,11544,27544,23844,14944,03939,61339,58839,48939,37339,69739,66039,56139,48438,768
Accumulated Depreciation1.9%18,62018,26618,44618,43218,25617,98517,92117,79818,49818,19218,15518,23618,73218,16218,57218,18217,70617,68617,28117,04916,623
Minority Interest11.1%60.0054.0054.0049.0071.0067.0066.0075.0070.0073.0069.0094.0094.0087.0084.0010295.0094.0087.00102131
Float----292,929---230,820---196,870---195,461---215,106-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations1156.1%3,0902467,7173,7041,3394,4305,6024,3024,7615,0954,7971,9901,2403,4101,5821,9187072384,2263,0841,336
  Share Based Compensation5.4%17616716416914514513913712011911713211199.0012612110883.0010111193.00
Cashflow From Investing-2696.2%-1,37653.00-334-11,443-2,359-1,748-962-1,077-1,173-12,049-1,061-2,625-686-4,697-2,086-782-1,628-663191-2,425368
Cashflow From Financing-25.3%-2,814-2,245-4,2693,758-2,054-1,554-2,702-1,777-3,0865,207-2,2742,262-2,0981,372-3,8511,137-1,490-2,011-3,152-2,084-1,614
  Dividend Payments5.3%1,9501,8521,8551,8851,8531,7501,7471,7701,7451,6431,6491,6731,6451,5421,5451,5771,5511,4051,3941,4681,428
  Buy Backs-69.0%122393466338149----18.00583239----1,2811,0501,4051,2351,090
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MRK Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Sales$ 15,775$ 14,487
Costs, Expenses and Other  
Cost of sales3,5403,926
Selling, general and administrative2,4832,479
Research and development3,9924,276
Restructuring costs12367
Other (income) expense, net(33)89
Total Costs, Expenses and Other10,10510,837
Income Before Taxes5,6703,650
Taxes on Income903825
Net Income4,7672,825
Less: Net Income Attributable to Noncontrolling Interests54
Net Income Attributable to Merck & Co., Inc.$ 4,762$ 2,821
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)$ 1.88$ 1.11
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)$ 1.87$ 1.11

MRK Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets  
Cash and cash equivalents$ 5,579$ 6,841
Short-term investments40252
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023)11,36610,349
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)6,5106,358
Other current assets7,9508,368
Total current assets31,44532,168
Investments280252
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 202323,04523,051
Goodwill21,18121,197
Other Intangibles, Net17,57218,011
Other Assets12,32611,996
Total Assets105,849106,675
Current Liabilities  
Loans payable and current portion of long-term debt3,0771,372
Trade accounts payable3,5143,922
Accrued and other current liabilities14,10215,766
Income taxes payable2,3982,649
Dividends payable2,0081,985
Total current liabilities25,09925,694
Long-Term Debt31,14233,683
Deferred Income Taxes922871
Other Noncurrent Liabilities8,2628,792
Merck & Co., Inc. Stockholders’ Equity  
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 20231,7881,788
Other paid-in capital44,59844,509
Retained earnings56,69753,895
Accumulated other comprehensive loss(5,274)(5,161)
Stockholders' equity before deduction for treasury stock97,80995,031
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 202357,44557,450
Total Merck & Co., Inc. stockholders’ equity40,36437,581
Noncontrolling Interests6054
Total equity40,42437,635
Liabilities and Equity$ 105,849$ 106,675
MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
 CEO
 WEBSITEmerck.com
 INDUSTRYPharmaceuticals
 EMPLOYEES65535

Merck & Co Inc Frequently Asked Questions


What is the ticker symbol for Merck & Co Inc? What does MRK stand for in stocks?

MRK is the stock ticker symbol of Merck & Co Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merck & Co Inc (MRK)?

As of Thu Jun 13 2024, market cap of Merck & Co Inc is 327.64 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers. The fair value of Merck & Co Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merck & Co Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merck & Co Inc a good stock to buy?

The fair value guage provides a quick view whether MRK is over valued or under valued. Whether Merck & Co Inc is cheap or expensive depends on the assumptions which impact Merck & Co Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRK.

What is Merck & Co Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, MRK's PE ratio (Price to Earnings) is 142.08 and Price to Sales (PS) ratio is 5.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merck & Co Inc's stock?

In the past 10 years, Merck & Co Inc has provided 0.118 (multiply by 100 for percentage) rate of return.